Koninklijke Philips N.V. Q1 2026 Earnings Recap

The 3.7% stock gain reflects investor approval of Philips’ solid order intake growth, expanding margins, and clear execution on innovation, despite ongoing macro uncertainties.

Key Takeaways

• Order intake rose 6% in Q1, led by equipment growth in Diagnostic & Treatment (D&T) and Connected Care segments.
• Comparable sales increased 4%, driven by broad-based segment contributions and particularly strong personal health performance.
• Adjusted EBITDA margin expanded by 40 basis points to 9%, marking the sixth consecutive quarter of margin improvement despite inflationary pressures such as higher tariffs.
• Innovation momentum remains strong, with 20 FDA 510(k) clearances and premarket approvals—more than doubling year-over-year—including AI-driven solutions in MRI, CT, and Image Guided Therapy.
• North America and Europe sustained leadership in growth, supported by enterprise partnerships and expanded retail distribution channels globally.